BioCentury
ARTICLE | Financial News

Celtaxsys raises $40 million series D

June 9, 2015 2:10 AM UTC

Celtaxsys Inc. (Atlanta, Ga.) raised $40 million in a series D round led by Domain Associates, which invested through its Fund VIII. Also participating were Lumira Capital; RMI Partners; Masters Capital Management; and the Georgia Research Alliance Venture Fund. Cystic Fibrosis Foundation Therapeutics, the drug development affiliate of the Cystic Fibrosis Foundation, provided Celtaxsys with a separate $5 million grant.

Celtaxsys plans to run a Phase II trial of lead compound CTX-4430 to treat CF. In February, FDA granted Orphan Drug designation to the leukotriene A4 hydrolase ( LTA4H) inhibitor for the indication. The company also expects data in 1Q16 from a Phase II study of CTX-4430 to treat moderately severe acne vulgaris. ...